Cargando…
A novel combination treatment against melanoma with NRAS mutation and therapy resistance
Targeted cancer therapies have shown some progress in treating BRAF‐mutant melanoma, but not against NRAS‐mutant and treatment‐resistant melanoma. In this issue of EMBO Molecular Medicine, Echevarría‐Vargas et al (2018) report that cotargeting BET and MEK pathways efficiently kills immune therapy‐re...
Autor principal: | Yu, Yanlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938621/ https://www.ncbi.nlm.nih.gov/pubmed/29661909 http://dx.doi.org/10.15252/emmm.201708573 |
Ejemplares similares
-
NRAS-driven melanoma: A RAF can hide another
por: Druillennec, Sabine, et al.
Publicado: (2017) -
Antifibrotic drugs as therapeutic tools in resistant melanoma
por: Sanchez‐Laorden, Berta, et al.
Publicado: (2022) -
Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017) -
Therapy resistance on the RADar in ovarian cancer
por: Schwickert, Jonas, et al.
Publicado: (2021) -
A novel approach to develop anti-virulence agents against group A streptococcus
por: Xu, Yuanxi, et al.
Publicado: (2012)